Jeffrey Crawford, MD

Professor of Medicine
George Barth Geller Distinguished Professor of Immunology
Member of the Duke Cancer Institute
Campus mail 443 Seeley G. Mudd Bldg, Durham, NC 27710
Phone (919) 681-9509
Email address crawf006@mc.duke.edu

1. Lung cancer/new treatment approaches.
2. Clinical trials of hematopoietic growth factors, biological agents and targeted drug development.
3. Cancer in the elderly and supportive care

Accomplishments

1. Lead Investigator of the U. S. multicenter, randomized trial of Filgrastim (G-CSF, Neupogen) to reduce the morbidity of chemotherapy-related neutropenia, leading to FDA approval 2/91.
2. Lead Investigator of the U. S. multicenter, randomized trial of Vinorelbine (Navelbine) in treatment of patients with advanced non small cell carcinoma of lung (NSCLC), leading to FDA approval 12/94.
3. Principal Investigator in initial phase I clinical trials of stem cell factor (SCF), megakaryocyte growth and development factor (MGDF), pegylated granulocyte-colony-stimulating factor and other novel hematopoietic growth factors.

In Their Words

Education and Training

  • M.D., Ohio State University, 1974

Publications

Ahn, Myung-Ju, Chao-Hua Chiu, Ying Cheng, Ji-Youn Han, Sarah B. Goldberg, Alastair Greystoke, Jeffrey Crawford, et al. “Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis.” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 15, no. 4 (April 2020): 637–48. https://doi.org/10.1016/j.jtho.2019.12.113.

PMID
31887431
Full Text

Cao, Xiaowen, Apar Kishor Ganti, Thomas Stinchcombe, Melisa L. Wong, James C. Ho, Chen Shen, Yingzhou Liu, Jeffery Crawford, Herbert Pang, and Xiaofei Wang. “Predicting risk of chemotherapy-induced severe neutropenia: A pooled analysis in individual patients data with advanced lung cancer.” Lung Cancer 141 (March 2020): 14–20. https://doi.org/10.1016/j.lungcan.2020.01.004.

PMID
31926983
Full Text

Mahtani, Reshma, Jeffrey Crawford, Robert Rifkin, David Dale, Alan Brookhart, Prasad Gawade, Tatiana Lawrence, Rejesh Balani, and Gary H. Lyman. “Abstract OT1-05-01: The incidence of febrile neutropenia (FN) for chemotherapy patients receiving pegfilgrastim by an on-body injector (pegfilgrastim OBI) versus other FN prophylaxis strategies.” In Ongoing Clinical Trials. American Association for Cancer Research, 2020. https://doi.org/10.1158/1538-7445.sabcs19-ot1-05-01.

Full Text

Crawford, Jeffrey, Neelima Denduluri, Debra Patt, Xiaolong Jiao, Phuong Khanh Morrow, Jacob Garcia, Richard Barron, and Gary H. Lyman. “Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer.” In Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer, 28:925–32, 2020. https://doi.org/10.1007/s00520-019-04875-1.

PMID
31172284
Full Text

Langer, Corey J., Mary W. Redman, James L. Wade, Charu Aggarwal, Jeffrey D. Bradley, Jeffrey Crawford, Philip J. Stella, et al. “SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study).” J Thorac Oncol 14, no. 10 (October 2019): 1839–46. https://doi.org/10.1016/j.jtho.2019.05.029.

PMID
31158500
Full Text

Bauer, Juergen, John E. Morley, Annemie M. W. J. Schols, Luigi Ferrucci, Alfonso J. Cruz-Jentoft, Elsa Dent, Vickie E. Baracos, et al. “Sarcopenia: A Time for Action. An SCWD Position Paper.” Journal of Cachexia, Sarcopenia and Muscle 10, no. 5 (October 2019): 956–61. https://doi.org/10.1002/jcsm.12483.

PMID
31523937
Full Text

Tan, Irena, Thomas E. Stinchcombe, Neal E. Ready, Jeffrey Crawford, Michael B. Datto, Rebecca J. Nagy, Richard B. Lanman, Lin Gu, and Jeffrey M. Clarke. “Therapeutic outcomes in non-small cell lung cancer with BRAF mutations: a single institution, retrospective cohort study.” Transl Lung Cancer Res 8, no. 3 (June 2019): 258–67. https://doi.org/10.21037/tlcr.2019.04.03.

PMID
31367539
Full Text

Negrao, Marcelo Vailati, Victoria M. Raymond, Richard B. Lanman, Patrick Kwok Shing Ng, Rebecca Nagy, Kimberly Banks, Viola Weijia Zhu, et al. “Molecular biology and treatment strategies for non-V600 BRAF-mutant NSCLC.” In Journal of Clinical Oncology, 37:3102–3102. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.3102.

Full Text

Ahn, M. -. J., C. -. H. Chiu, Y. Cheng, J. -. Y. Han, S. B. Goldberg, A. Greystoke, J. Crawford, et al. “Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC: The AURA LM study.” In Ann Oncol, 30 Suppl 2:ii48, 2019. https://doi.org/10.1093/annonc/mdz063.003.

PMID
32131251
Full Text

Pages